Tumefactive demyelination presenting during bevacizumab treatment

We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ case reports 2015-12, Vol.2015, p.bcr2015212173
Hauptverfasser:	Rice, Claire M, Rossiter, David, Fehmi, Janev, Stevens, James C, Renowden, Shelley A, Cohen, Nicki, Bailey, Clare, Scolding, Neil J
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Bevacizumab - administration & dosage Bevacizumab - adverse effects Biopsy Child Choroidal Neovascularization - pathology Clinical trials Demyelinating Diseases - cerebrospinal fluid Demyelinating Diseases - chemically induced Demyelinating Diseases - pathology Edema Europe (West) Female Follow-Up Studies Humans Immunotherapy Intravitreal Injections Monoclonal antibodies Multiple sclerosis Treatment Outcome Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions Vascular endothelial growth factor Visual acuity White
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.
ISSN:	1757-790X 1757-790X
DOI:	10.1136/bcr-2015-212173